Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

You may also like

11 April 2013

OneVentures team ‘charmed’ by Queensland Health-IT company

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

14 October 2021

Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis

02 August 2020

FDA Approves Xeglyze™ for the topical treatment of head lice infestation

29 January 2014

Scale Investment in Paloma

16 March 2020

OneVentures invests in international software company Phocas, bringing business back to Australia and positioning the company for international expansion

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor
clear Close